Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marriott International Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.97 (market cap $29.60B), while Marriott International Inc trades at $355.57 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Marriott International Inc pays a 0.84% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MAR | |
|---|---|---|
Market Cap | $29.60B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $402.54 |
52-Week Low | $205.48 | $259.04 |
Enterprise Value | $27.56B | $108.45B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Marriott International (MAR) trades at $356.31, up 2.26% today, with a bearish technical signal from moving averages. Recent Q2 2026 earnings beat estimates with EPS of $3.19 versus $3.08 expected, driven by strong fee revenue growth. The company raised its 2026 outlook, supported by a record pipeline and AI-powered booking tools, though valuation remains elevated with a P/E of 36.18.
Outlook is mixed: analyst consensus targets $387.31 (8.7% upside) with 44% buy ratings, but high debt and Middle East weakness pose risks. The stock offers growth via fee-based model and dividends, but requires monitoring of RevPAR trends and macroeconomic pressures for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
